Worldwide first artificial Human Platelet Lysate (HPL) solution – a key ingredient for the research & production of cell-based pharmaceutical...
Qosina, a global leader in the distribution of single-use medical and biopharmaceutical components, is proud to announce a new strategic partnership with...
GeneFab, a next-generation cell and gene therapy-focused contract research, development, and manufacturing organization (CRDMO), has partnered with RegCe...
Global CDMO supports South Korean company on a multiphase project at its Copenhagen and Chiba sites AGC Biologics, your friendly CDMO expert, ...
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentat...
Along with PCI’s own robust infrastructure expansions, acquisition furthers CDMO’s recent growth in sterile fill-finish, advanced drug delivery...
Biomanufacturers producing protein biologics including complex modalities, will have access to a full suite of custom cell line developme...
Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $...
Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into ...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd announced a settlement and license agreement...
Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network Hypothermic pres...
Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjug...
Mabion S.A. ("Mabion"), a leading Polish CDMO specializing in the development and manufacturing of biopharmaceuticals for third parties, and Instituto de B...
As Asia accounts for nearly half of the world’s cancer burden, the push toward precision medicine is more critical than ever. In this...
© 2025 Biopharma Boardroom. All Rights Reserved.
